These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30504807)

  • 41. Women with von Willebrand disease.
    Scharrer I
    Hamostaseologie; 2004 Feb; 24(1):44-9. PubMed ID: 15029272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G; Tosetto A; Federici AB; Rodeghiero F
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
    Hancock JM; Escobar MA
    Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of menstrual cycle on platelet aggregation in reproductive-age women.
    Melamed N; Yogev Y; Bouganim T; Altman E; Calatzis A; Glezerman M
    Platelets; 2010; 21(5):343-7. PubMed ID: 20433309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The length of the sanitary napkins can be used as a handier index than pictorial blood loss assessment chart to predict the heavy menstrual bleeding.
    Nagao A; Tokugawa T; Matsuo Y; Shirayama R; Morishita E; Nozima M; Kinai E; Nishida Y; Fukutake K
    J Obstet Gynaecol Res; 2023 Jul; 49(7):1838-1845. PubMed ID: 37141923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
    de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
    Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study.
    Kirtava A; Drews C; Lally C; Dilley A; Evatt B
    Haemophilia; 2003 May; 9(3):292-7. PubMed ID: 12694520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women.
    Miller CH; Dilley A; Richardson L; Hooper WC; Evatt BL
    Am J Hematol; 2001 Jun; 67(2):125-9. PubMed ID: 11343385
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The healthy female microbiome across body sites: effect of hormonal contraceptives and the menstrual cycle.
    Krog MC; Hugerth LW; Fransson E; Bashir Z; Nyboe Andersen A; Edfeldt G; Engstrand L; Schuppe-Koistinen I; Nielsen HS
    Hum Reprod; 2022 Jun; 37(7):1525-1543. PubMed ID: 35553675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of the menstrual and oral contraceptive cycle phases on microvascular reperfusion.
    Mattu AT; MacInnis MJ; Doyle-Baker PK; Murias JM
    Exp Physiol; 2020 Jan; 105(1):184-191. PubMed ID: 31625647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.
    Tosetto A; Badiee Z; Baghaipour MR; Baronciani L; Battle J; Berntorp E; Bodó I; Budde U; Castaman G; Eikenboom JCJ; Eshghi P; Ettorre C; Goodeve A; Goudemand J; Hay CRM; Hoorfar H; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Mazzucconi MG; Morfini M; Oldenburg J; Peake I; Parra Lòpez R; Peyvandi F; Schneppenheim R; Tiede A; Toogeh G; Trossaert M; Zekavat O; Zetterberg EMK; Federici AB
    J Thromb Haemost; 2020 Sep; 18(9):2145-2154. PubMed ID: 32379400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Von Willebrand disease in women with menorrhagia].
    Stefańska E; Vertun-Baranowska B; Windyga J; Łopaciuk S
    Ginekol Pol; 2004 Jan; 75(1):47-52. PubMed ID: 15112473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis.
    Laffan M; Sathar J; Johnsen JM
    Haemophilia; 2021 Feb; 27 Suppl 3():66-74. PubMed ID: 32578345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of Von Willebrand Disease (VWD) and pregnancy on the expression of angiogenic factors in the porcine female reproductive tract.
    Möller R; Kaiser K; Baulain U; Petersen B; Detering C; Ekhlasi-Hundrieser M; Pfarrer C; von Depka Prondzinski M; Lehner S
    Reprod Biol; 2022 Dec; 22(4):100700. PubMed ID: 36240670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.
    Peyvandi F; Mamaev A; Wang JD; Stasyshyn O; Timofeeva M; Curry N; Cid AR; Yee TT; Kavakli K; Castaman G; Sytkowski A
    J Thromb Haemost; 2019 Jan; 17(1):52-62. PubMed ID: 30362288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Choroidal thickness changes during the menstrual cycle.
    Ulaş F; Doğan U; Duran B; Keleş A; Ağca S; Celebi S
    Curr Eye Res; 2013 Nov; 38(11):1172-81. PubMed ID: 23841496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.
    Ragni MV; Jankowitz RC; Jaworski K; Merricks EP; Kloos MT; Nichols TC
    Thromb Haemost; 2011 Oct; 106(4):641-5. PubMed ID: 21833452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes.
    Lethagen S; Hillarp A; Ekholm C; Mattson E; Halldén C; Friberg B
    Thromb Haemost; 2008 Jun; 99(6):1013-8. PubMed ID: 18521502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.